# Biobanking Market > Biobanking Market Research Report: Size, Share, Trend Analysis By Sample Type (Blood Products, Tissues, Cells, Nucleic Acids, Microbiome Samples), By Applications (Research and Development, Clinical Trials, Personalized Medicine, Regenerative Medicine), By End-use (Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, Government Organizations), By Storage Type (Vapor Phase Storage, Liquid Phase Storage, Cryopreservation Storage), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.12% - **2024:** $ 75.39 Billion - **2025:** $ 78.5 Billion - **2035:** $ 117.55 Billion - **Key Players:** Companies such as Thermo Fisher Scientific (US), Qiagen (DE), Illumina (US), Merck KGaA (DE), STEMCELL Technologies (CA), BioLife Sciences (US), Tecan Group (CH), Biosample Solutions (US), ReproCELL (JP) are some of the major participants in the global market. **Report ID:** MRFR/HC/4511-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/biobanking-market-5967 --- ## Market Summary ## **Biobanking Market Overview** As per MRFR analysis, the Biobanking Market Size was estimated at 4.93 (USD Billion) in 2023. The Biobanking Market is expected to grow from 5.14 (USD Billion) in 2024 to 8 (USD Billion) by 2035. The Biobanking Market CAGR (growth rate) is expected to be around 4.1% during the forecast period (2025 - 2035). ### **Key Biobanking Market Trends Highlighted** A number of important variables are propelling the notable expansion of the Biobanking Market. The growing need for targeted therapeutics and customized medicine, which necessitate large biobanks that supply a variety of biological samples, is one of the main factors propelling the market. Global biobanking efforts are also being accelerated by developments in genomics and biotechnology, as nations make significant infrastructural investments to improve research capacities. Funding and policy support have increased as a result of governments and organizations realizing the value of biobanks for disease and public health research, which has aided in the growth of international biobank networks. The Biobanking Market is experiencing a significant expansion in opportunities. Collaboration between pharmaceutical firms and biobanks has the potential to result in advances in drug development and a deeper comprehension of illnesses. Furthermore, incorporating AI and machine learning into biobank operations can improve sample handling and data processing, generating new insights and efficiency. These new technologies provide biobanks a critical chance to boost their worth and research utility. Current patterns show that biobanking is moving toward uniform procedures and laws across geographical boundaries. International research partnerships are facilitated by efforts to standardize sample collection, storage, and dissemination procedures, which enhance biorepositories' quality and credibility. Additionally, ethical issues and informed consent—which guarantees that participants are aware of how their biological samples will be used—are becoming more and more important. Growing public knowledge of biobanks emphasizes the need of openness and participation, which will strengthen the foundation for biobanking projects in the long run. All of these patterns point to a vibrant and changing Biobanking Market. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **Biobanking Market Drivers** ### **Increasing Prevalence of Chronic Diseases** The Biobanking Market is significantly driven by the rising incidence of chronic diseases such as cancer, diabetes, and cardiovascular diseases. According to the World Health Organization, chronic diseases are responsible for approximately 71% of all deaths globally, with cancer cases projected to increase by about 60% over the next two decades. Established organizations such as the American Cancer Society and the European Society for Medical Oncology have been actively promoting strategies for cancer research and patient management, which includes biobanking. By providing vital biological samples for Research and Development (R&D), biobanks are crucial in understanding disease mechanisms and developing new therapeutic approaches. With the increasing focus on personalized medicine and targeted therapies, the demand for biobanking services is set to rise, further driving market growth in the Biobanking Market. ### **Advancements in Genomic Research** Advancements in genomic research and technologies are propelling the growth of the Biobanking Market. The completion of the Human Genome Project and ongoing research initiatives by entities like the National Institutes of Health have generated vast amounts of genomic data. As new genomic technologies proliferate, the demand for biological specimens for genetic analysis is expanding. A report from the National Human Genome Research Institute has highlighted that the availability of biobanks is critical for advancing genomic and precision medicine, leading to tailor-made treatments based on individual genetic profiles. This shift towards personalized healthcare encourages the establishment and expansion of biobanks globally, thus bolstering market prospects. ### **Government Initiatives for Biobanking** Governments around the world are increasingly recognizing the importance of biobanking in healthcare and research, leading to supportive initiatives and policies. For instance, in 2022, the European Commission announced significant funding for biobanking projects aimed at facilitating research on rare diseases and precision medicine across Europe. Such initiatives emphasize collaboration between public institutions and private sectors, thereby enhancing the operational landscape of the Biobanking Market. As governments invest in biobanking infrastructure and regulatory frameworks, the accessibility of biological samples improves, encouraging research partnerships and driving market growth. ## **Biobanking Market Segment Insights** ### **Biobanking Market Sample Type Insights** The Biobanking Market focused heavily on various sample types, which play a critical role in the research and development of medical and biological sciences. Blood Products led this segment with a valuation of 1.5 USD Billion in 2024, and it is expected to rise to 2.4 USD Billion by 2035, making it a major player due to the extensive use of blood for diagnostics and therapeutic developments. Tissues were valued at 1.2 USD Billion in 2024 and are anticipated to grow to 1.9 USD Billion by 2035, reflecting the increasing utilization of tissue samples in regenerative medicine and cancer research. Cells also held a notable position, valued at 1.4 USD Billion in 2024 and projected to reach 2.2 USD Billion in 2035. The importance of cells, particularly stem cells, in clinical therapies and drug discovery drove their market significance. Nucleic Acids, essential for genetic research and personalized medicine, registered a valuation of 0.8 USD Billion in 2024 and are expected to expand to 1.3 USD Billion by 2035, showcasing the growing focus on genomics. Meanwhile, Microbiome Samples, while the least valued at 0.24 USD Billion in 2024, are projected to see a slight decrease to 0.2 USD Billion in 2035, reflecting evolving research interests in microbiomes and their implications in health and disease. Each of these sample types presented unique opportunities and challenges within the Biobanking Market, driven by trends in healthcare research, advancements in technologies, and a growing healthcare data management landscape. These segments not only contributed to the overall valuation of the market but also provided invaluable resources for medical breakthroughs and innovations. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ### **Biobanking Market Application Insights** The Biobanking Market, specifically within the Application segment, plays a crucial role in advancing healthcare and research initiatives worldwide. This segment encompasses vital areas such as Research and Development, Clinical Trials, Personalized Medicine, and Regenerative Medicine. Research and Development is integral as it underpins innovation, providing researchers with critical biological samples for various studies. Clinical Trials are significantly bolstered by biobanks, as they supply essential data that enhances the efficiency and effectiveness of testing new therapies. Personalized Medicine is gaining momentum, driven by advancements in genetic research that enable tailored patient treatment strategies based on biobanked samples. Regenerative Medicine focuses on creating therapies to restore damaged tissues and organs, emphasizing the importance of biobanking in developing future healthcare solutions. The Biobanking Market data indicates strong growth opportunities, primarily driven by technological advancements and increased funding for biomedical research, although challenges such as regulatory compliance and ethical concerns persist in this evolving industry. ### **Biobanking Market End-use Insights** The Biobanking Market is witnessing significant growth, driven by a strong demand across various End-use sectors, primarily in Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, and Government Organizations. Academic Research Institutions play a pivotal role as they utilize biobanks to conduct advanced genetic research and clinical trials, supporting the evolving landscape of personalized medicine. Biotechnology Companies are also major contributors, leveraging biobanking resources to innovate and develop new therapies, which enhances their competitive edge in the industry. Pharmaceutical Companies increasingly depend on biobanks for drug discovery and validation processes, emphasizing their importance in bringing new therapeutics to market efficiently. Government Organizations support biobank initiatives through funding and regulatory frameworks, facilitating the integration of biobanks into public health strategies. Together, these sectors represent the backbone of the Biobanking Market, underscoring the relevance of biobanks in advancing healthcare, ensuring compliance, and supporting research initiatives worldwide. The overall market growth is further propelled by increasing investments in healthcare and technological advancements in biobanking procedures. ### **Biobanking Market Storage Type Insights** Within the market, the Storage Type segment plays a crucial role, encompassing various storage methods essential for the preservation of biological samples. The segment can be defined through methods such as Vapor Phase Storage, Liquid Phase Storage, and Cryopreservation Storage. Vapor Phase Storage is increasingly gaining traction due to its capacity to maintain samples at ultra-low temperatures, thus ensuring sample integrity over extended periods. Liquid Phase Storage remains a favored choice for various biobanking applications, as it provides stable conditions that allow for a wide range of biological materials to be preserved effectively. Cryopreservation Storage is critical in the biobanking industry, facilitating long-term storage solutions for cells and tissues while ensuring their viability for research and clinical applications. The combination of these storage types is vital as they not only meet regulatory requirements but also cater to the evolving needs of research and healthcare sectors, propelling the Biobanking Market growth while addressing demands for high-quality preservation techniques. ### **Biobanking Market Regional Insights** The Biobanking Market showed substantial regional diversification, with North America leading the way in market value, estimated at 2.3 USD Billion in 2024 and projected to reach 3.5 USD Billion in 2035. This region displayed majority holding, driven by strong Research and Development initiatives and advanced healthcare infrastructure. Europe followed with a valuation of 1.4 USD Billion in 2024 and 2.1 USD Billion in 2035, where innovative biobanking practices and stringent regulations support the industry's growth. In South America, the market was valued at 0.3 USD Billion in 2024, with an expected rise to 0.5 USD Billion by 2035, reflecting increasing awareness about biobanking and its applications. Asia Pacific, valued at 0.9 USD Billion in 2024 and 1.4 USD Billion in 2035, showed significant potential as growing investment in biotechnology and healthcare fuels market growth. The Middle East and Africa, although smaller at 0.2 USD Billion in 2024 with an increase to 0.5 USD Billion by 2035, emerged slowly due to government initiatives in improving healthcare services and biobanking facilities. The nuances across these regions highlighted varied opportunities, challenges, and trends shaping the Biobanking Market dynamics and overall market growth. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **Biobanking Market Key Players and Competitive Insights** The Biobanking Market is a rapidly evolving sector with significant competitive dynamics that reflect its importance in healthcare, research, and diagnostics. As biobanks store biological samples essential for developing personalized medicine, drug discovery, and various genetic studies, understanding the competition among key players becomes crucial for stakeholders. The market is characterized by numerous organizations implementing strategic initiatives such as collaborations, mergers, and acquisitions to enhance their technological capabilities and expand their geographical footprint. This competitive landscape underscores the importance of innovation and quality in biobanking services and solutions, as companies vie to establish themselves as leaders in this essential industry. Becton Dickinson holds a prominent position in the Biobanking Market, primarily due to its advanced product offerings and strong commitment to innovation. The company's strengths lie in its technical expertise and comprehensive range of biobanking solutions, which include specialized collection devices, storage systems, and preservation technologies that cater to the needs of various biobanking operations. Through sustained investments in research and development, Becton Dickinson has successfully integrated cutting-edge technologies into its products, enhancing efficiency and quality in sample handling and preservation. The company's extensive global reach further solidifies its market presence, establishing it as a trusted provider of biobanking solutions essential for research and clinical applications. Biolife Solutions operates as a significant player in the Biobanking Market, recognized for its innovative cryopreservation services and solutions. With a focus on high-performance biopreservation media and related products, Biolife Solutions delivers essential tools that support the preservation and transportation of biological samples, thereby sustaining their viability over time. The company's approach has led to a strong market presence, supported by strategic collaborations and acquisitions to broaden its product portfolio and scale its services across the global landscape. Biolife Solutions has built a reputation for high-quality standards and reliability in the biobanking sector, making it a preferred partner for researchers and institutions engaged in critical biological studies and regenerative medicine. Through its continuous focus on technological advancements and customer satisfaction, Biolife Solutions aims to enhance its competitive edge in the evolving landscape of the Biobanking Market. ### **Key Companies in the Biobanking Market Include** - Becton Dickinson - Biolife Solutions - Charles River Laboratories - BioCision - Thermo Fisher Scientific - STEMCELL Technologies - Reprocell - VWR Corporation - USA Biologics - Procurement Services - Genomatica - Asterand Bioscience - Qiagen - SigmaAldrich - Merck KGaA ### **Biobanking Market Developments** In an effort to increase diversity and advance personalized medicine initiatives, the U.S. National Institutes of Health (NIH) extended the All of Us Research Program in June 2025 to include the biospecimens of 500,000 more individuals. In order to strengthen domestic sample integrity and supply, Thermo Fisher Scientific stated in May 2025 that it will invest $2 billion to modernize cold-chain and analytical facilities inside its biobanking division in North America. With £45 million in financing, a partnership led by Genomics England and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) launched Project Genome of Europe in March 2025 with the goal of accelerating pan-EU research collaborations and harmonizing cross-national biobanking standards. In order to strengthen Asia-Pacific research capacity, AIG Hospital in southern India launched its first regional biobank in November 2024 with the goal of collecting and storing over 100,000 tissue and blood samples over the next ten years. Initial results showing effective federated learning deployment across biobanks for multiple sclerosis research were released in October 2024 by the Clinnova effort, a cooperation between France, Germany, Switzerland, and Luxembourg, emphasizing privacy protection and interoperability. The European biobanking network, BBMRI-ERIC, announced in April 2024 that the number of participating institutions had increased by 12%, indicating improved standardization and sample-sharing capabilities. Additionally, around 25% of biobanks in North America explored blockchain initiatives in early 2024 to safeguard data access and sample tracking processes. ## **Biobanking Market Segmentation Insights** ### **Biobanking Market Sample Type Outlook** - Blood Products - Tissues - Cells - Nucleic Acids - Microbiome Samples ### **Biobanking Market Application Outlook** - Research and Development - Clinical Trials - Personalized Medicine - Regenerative Medicine ### **Biobanking Market End-use Outlook** - Academic Research Institutions - Biotechnology Companies - Pharmaceutical Companies - Government Organizations ### **Biobanking Market Storage Type Outlook** - Vapor Phase Storage - Liquid Phase Storage - Cryopreservation Storage ### **Biobanking Market Regional Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Africa ## Market Drivers ### Market Growth Projections The Global Biobanking Market Industry is projected to experience substantial growth, with estimates indicating a market value of 5.14 USD Billion in 2024 and a potential increase to 8 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 4.1% from 2025 to 2035.   Factors contributing to this expansion include increasing demand for [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937), advancements in technology, and growing investment in research and development. As the market evolves, it is likely to attract further interest from stakeholders across various sectors, including healthcare, pharmaceuticals, and biotechnology. ### Regulatory Support and Standardization Regulatory support and standardization are pivotal in shaping the Global Biobanking Market Industry. Governments are establishing frameworks to ensure ethical practices in biobanking, which enhances public trust and encourages participation. Standardization of sample collection, processing, and storage protocols is essential for maintaining data integrity and reproducibility in research.   As regulatory bodies continue to refine guidelines, biobanks are better positioned to meet the demands of researchers and healthcare providers. This regulatory environment is likely to contribute to the market's growth, with projections indicating a rise to 5.14 USD Billion in 2024. ### Rising Awareness of Biobanking Benefits Rising awareness of the benefits of biobanking is driving participation and investment in the Global Biobanking Market Industry. Educational initiatives aimed at healthcare professionals and the public are highlighting the critical role biobanks play in advancing medical research and improving patient care.   Increased understanding of how biobanks contribute to disease prevention, diagnosis, and treatment is likely to enhance public willingness to donate biological samples. This heightened awareness is expected to support the market's growth, with projections indicating a rise to 5.14 USD Billion in 2024 and further growth towards 8 USD Billion by 2035. ### Technological Advancements in Biobanking Technological advancements are transforming the Global Biobanking Market Industry, enabling more efficient sample management and data analysis. Innovations such as automated sample processing, advanced biorepositories, and sophisticated [data analytics](https://www.marketresearchfuture.com/reports/data-analytics-market-1689) tools are enhancing the operational capabilities of biobanks.   These technologies facilitate the integration of large datasets, allowing for more comprehensive research outcomes. As a result, biobanks can better support personalized medicine initiatives and large-scale epidemiological studies. The market's growth trajectory, with an expected value of 8 USD Billion by 2035, is indicative of the significant impact that technology has on biobanking practices. ### Increasing Demand for Personalized Medicine The Global Biobanking Market Industry is witnessing a surge in demand for personalized medicine, which relies heavily on biobanks for genetic and biological samples. This trend is driven by advancements in genomics and biotechnology, enabling tailored treatments for various diseases.   For instance, biobanks facilitate the identification of genetic markers associated with specific conditions, thereby enhancing the efficacy of therapies. As the market evolves, the value is projected to reach 5.14 USD Billion in 2024, with expectations of expanding to 8 USD Billion by 2035, reflecting a compound annual growth rate of 4.1% from 2025 to 2035. ### Growing Investment in Research and Development Investment in research and development within the Global Biobanking Market Industry is on the rise, as governments and private entities recognize the importance of biobanks in advancing medical research. Funding initiatives are increasingly directed towards biobanking infrastructure, which supports the collection, storage, and analysis of biological samples.   This investment not only enhances the capabilities of biobanks but also fosters collaboration between academic institutions and industry stakeholders. The anticipated growth in the market, reaching 8 USD Billion by 2035, underscores the critical role that R&D plays in driving innovation and improving healthcare outcomes. ## Future Outlook The Biobanking Market size is projected to reach USD 117.55 Billion by 2035, growing at a CAGR of 4.12%, driven by advancements in personalized medicine, increased research funding, and technological innovations. **New opportunities:** - Expansion of biobanking services into emerging markets Development of automated sample processing technologies Partnerships with pharmaceutical companies for drug discovery initiatives By 2035, the Biobanking Market is expected to be robust, driven by strategic innovations and global collaborations. ## Segment Insights ### By Application: Research (Largest) vs. Clinical Trials (Fastest-Growing) In the Biobanking Market, the application segment is primarily dominated by Research, which accounts for a significant portion of the overall market share. Clinical Trials follow closely, benefiting from an ever-increasing focus on drug development and personalized medicine approaches. [Regenerative Medicine](https://www.marketresearchfuture.com/reports/regenerative-medicine-market-2220) and Pharmaceutical Development also contribute valuable segments but represent smaller proportions of the total application landscape. Together, these segments highlight an increasingly diversified approach within biobanking services to cater to various research needs and healthcare advancements. Research (Dominant) vs. Regenerative Medicine (Emerging) Research remains the dominant application within the biobanking sector, serving as a critical backbone for academic and clinical studies alike. It involves the collection, processing, and storage of biological samples that are essential for advancing scientific knowledge and medical innovations. In contrast, Regenerative Medicine is emerging rapidly, driven by advancements in stem cell research and tissue engineering, which aim to restore or replace damaged tissues and organs. Although still developing, Regenerative Medicine is capturing attention and investment, signaling its potential to reshape treatment paradigms in the future. ### By Sample Type: Blood (Largest) vs. Tissue (Fastest-Growing) In the Biobanking Market, blood samples hold the largest market share, driven by their critical role in various medical and research applications such as diagnostics, therapeutic monitoring, and disease prevention. Tissue samples, while currently smaller in market share, are emerging as a significant contributor due to advancements in regenerative medicine and personalized therapies. The demand for diverse biological materials to support research is leading to an increase in tissue-banking initiatives, widening their application scope. The growth trends within the sample type segment are influenced by technological advancements and an increase in research activities. Blood samples are well-established and continue to dominate due to their ease of collection and extensive applications. However, tissue samples are gaining traction rapidly as innovations in sample preservation and analysis techniques enhance their utilization. The rising number of clinical trials and research studies focusing on tissue-based therapies significantly contributes to the robust growth of this segment. Blood (Dominant) vs. Tissue (Emerging) Blood samples are undeniably the dominant player in the Biobanking Market, primarily due to their ease of accessibility and extensive use across various research fields, including genomics and immunology. They contribute significantly to studies related to disease mechanisms and treatment outcomes. On the other hand, tissue samples represent an emerging segment with substantial growth potential driven by breakthroughs in regenerative medicine and personalized treatments. The complexity of processing and storage of tissue samples poses challenges; however, advancements in bioprocessing technology are transforming their viability in research. As both segments continue to evolve, the interplay between blood and tissue samples is expected to fuel innovations, enhancing their market relevance and application. ### By Storage Type: Cryopreservation (Largest) vs. Liquid Nitrogen Storage (Fastest-Growing) The storage type segment exhibits diverse preferences, with Cryopreservation holding the largest Biobanking Market share. This method is widely adopted for preserving biological samples, particularly cells and tissues, due to its effectiveness in maintaining viability over extended periods. Additionally, Liquid Nitrogen Storage is gaining traction rapidly, indicating a growing preference for this advanced method among biobanks, especially for sensitive biological materials that require ultra-low temperatures for optimal preservation. Such demand is shaped by innovations in biorepositories and a surge in research activities. The growth trends within the storage type segment are largely fueled by advancements in storage technologies and increasing awareness of the importance of sample integrity. Cryopreservation continues to dominate as it is trusted for its reliability, while Liquid Nitrogen Storage is emerging as a popular choice because it allows for faster processing and handling of samples in laboratories. The increasing research investments in biotech and pharmaceuticals further drive the adoption of these storage techniques, aligning with the growing needs for efficient specimen handling in regenerative medicine and personalized therapies. Cryopreservation (Dominant) vs. Liquid Nitrogen Storage (Emerging) Cryopreservation is regarded as the dominant storage method in the market, providing a reliable solution for maintaining the integrity of biological specimens. Utilizing controlled freezing techniques, biobanks ensure long-term preservation of complex samples such as stem cells and various tissues, thus, facilitating extensive research and clinical applications. On the other hand, Liquid Nitrogen Storage represents the emerging trend, characterized by its ability to operate at extremely low temperatures essential for preserving fragile biological entities without damage. This method is increasingly preferred due to its efficiency and adaptability to modern laboratory needs, resulting in enhanced operational capabilities in handling various samples. As biobanks continue to evolve, both Cryopreservation and Liquid Nitrogen Storage are crucial in supporting innovative research, with the latter quickly becoming a viable alternative for future applications. ### By End User: Academic Institutions (Largest) vs. Pharmaceutical Companies (Fastest-Growing) In the biobanking market, academic institutions represent the largest segment, encompassing universities and research organizations that play a critical role in biobanking activities. Their significant share is attributed to their extensive research initiatives that demand reliable biological sample storage. Pharmaceutical companies are also substantial players in this segment, with increasing investments aimed at drug development and personalized medicine, thus expanding their biobanking operations significantly. As a result, while academic institutions retain a large presence, pharmaceutical companies are rapidly gaining ground in this market. End User: Academic Institutions (Dominant) vs. Pharmaceutical Companies (Emerging) Academic institutions are dominant in the market due to their reliance on biobanks for research and advancement in biomedical sciences. They typically manage large volumes of diverse biological samples that serve various studies, from genetics to disease pathology. In contrast, pharmaceutical companies are emerging forces leveraging advanced biobanking technologies to enhance their research capabilities. These companies seek to utilize biobanks to identify new drug targets and validate therapeutic biomarkers, positioning themselves powerfully to adapt to the growing demand for personalized medicine and innovative therapeutic solutions. ## Regional Market Share Analysis ### North America : Market Leader in Biobanking North America leads in the Biobanking Market Size, accounting for over 53.06% of the global revenue in 2024. The region's growth is driven by increasing investments in healthcare research, advancements in biobanking technologies, and a robust regulatory framework that supports biobanking initiatives. The demand for personalized medicine and regenerative therapies further fuels this growth, as institutions seek to enhance their biobanking capabilities to meet evolving healthcare needs. The competitive landscape in North America is characterized by the presence of key players such as Thermo Fisher Scientific, Illumina, and BioLife Sciences. These companies are at the forefront of innovation, offering advanced biobanking solutions that cater to diverse research requirements. The U.S. and Canada are leading countries in this sector, with numerous biobanks established to support both academic and commercial research endeavors. The region's strong infrastructure and funding opportunities continue to attract investments, solidifying its position as a biobanking powerhouse. ### Europe : Emerging Biobanking Hub Europe Biobanking Market size was valued at USD 18.85 Billion in 2024, making it the second-largest regional market with a 25% share. The region benefits from strong governmental support and regulatory frameworks that promote biobanking initiatives. Increasing collaborations between academic institutions and biobanks, along with rising public awareness about the importance of biobanking in research, are key drivers of growth. The focus on personalized medicine and genetic research is also propelling demand for biobanking services across Europe. Leading countries in Europe include Germany, the UK, and France. Germany market is a strong plater with host of cutting-edge biobanking technologies, including fully automated robotic storage systems, AI-driven sample management, and integrated virtual platforms that enable seamless cross-institutional research. The Italy Market is witnessing exceptional progress in this market Italy boasts one of the most sophisticated networks under the BBMRI-ERIC (Biobanking and BioMolecular Resources Research Infrastructure) umbrella, with over 90 biobanks collaborating to standardize sample quality and ethical protocols. The Italy market is heavily concentrated on disease-specific biobanks, particularly for rare diseases, cardiovascular health, and various cancers. Italy’s progress in this market is promoting Europe as a critical region in this market which host numerous biobanks and research facilities.  Key players such as Qiagen and Merck KGaA are instrumental in driving innovation and expanding service offerings. The competitive landscape is characterized by a mix of established companies and emerging startups, fostering a dynamic environment for growth. As Europe continues to enhance its biobanking capabilities, it is set to play a crucial role in global health research. ### Asia-Pacific : Growing Biobanking Potential The Asia-Pacific region is witnessing a gradual rise in the biobanking market size, currently holding an 8.0% share as of 2024. This growth is primarily driven by increasing investments in healthcare infrastructure, rising awareness of biobanking's role in research, and government initiatives aimed at enhancing biobanking capabilities. The demand for biobanks is also fueled by the growing prevalence of chronic diseases and the need for personalized medicine solutions in the region.  Countries like Japan, China, and Australia are leading the charge in biobanking initiatives, with significant investments from both public and private sectors. Key players such as ReproCELL and STEMCELL Technologies are expanding their presence, contributing to the competitive landscape. As the region continues to develop its biobanking infrastructure, it is expected to see substantial growth in the coming years, positioning itself as a vital player in The Biobanking. ### Middle East and Africa : Emerging Market Opportunities The Middle East and Africa region is gradually emerging in the market, currently holding a modest 2.39% share as of 2024. The growth in this region is driven by increasing healthcare investments, rising awareness of biobanking's significance in research, and the establishment of regulatory frameworks to support biobanking initiatives. The demand for biobanked samples is expected to rise as healthcare systems evolve and focus on personalized medicine and research advancements. Countries like South Africa and the UAE are leading the way in developing biobanking capabilities, with several initiatives aimed at enhancing research infrastructure. The competitive landscape is characterized by a mix of local and international players, with a focus on building partnerships to improve biobanking practices. As the region continues to develop, opportunities for growth in biobanking are expected to expand significantly, driven by both public and private sector investments. ## Competitive Benchmarking The Biobanking Market is currently characterized by a dynamic competitive landscape, driven by advancements in technology, increasing demand for personalized medicine, and a growing emphasis on research and development. Key players such as Thermo Fisher Scientific (US), Qiagen (DE), and Illumina (US) are strategically positioned to leverage these trends. Thermo Fisher Scientific (US) focuses on innovation through its extensive portfolio of biobanking solutions, while Qiagen (DE) emphasizes partnerships to enhance its product offerings.   Illumina (US) is heavily invested in digital transformation, aiming to streamline operations and improve data management, which collectively shapes a competitive environment that is increasingly reliant on technological advancements and strategic collaborations.The market structure appears moderately fragmented, with a mix of established players and emerging companies. Key business tactics such as localizing manufacturing and optimizing supply chains are prevalent among major players. This approach not only enhances operational efficiency but also allows companies to respond swiftly to regional demands. The collective influence of these key players fosters a competitive atmosphere where innovation and strategic positioning are paramount.   In November Thermo Fisher Scientific (US) announced the launch of a new biobanking platform designed to enhance sample management and data integration. This strategic move is significant as it positions the company to meet the increasing demand for efficient biobanking solutions, particularly in the context of personalized medicine. By streamlining sample tracking and data analysis, Thermo Fisher aims to solidify its market leadership and cater to the evolving needs of researchers and healthcare providers.   In October Qiagen (DE) expanded its collaboration with a leading academic institution to develop advanced biobanking protocols. This partnership is indicative of Qiagen's strategy to enhance its research capabilities and broaden its product offerings. By aligning with academic leaders, Qiagen not only strengthens its innovation pipeline but also gains access to cutting-edge research that could inform future product development.   In September Illumina (US) unveiled a new AI-driven analytics tool aimed at improving biobanking data interpretation. This tool is expected to revolutionize how researchers analyze genetic data, thereby enhancing the overall utility of biobanked samples. The integration of AI into biobanking operations reflects a broader trend towards digitalization, positioning Illumina as a frontrunner in leveraging technology to enhance research outcomes.   As of December current competitive trends in the Biobanking Market are heavily influenced by digitalization, sustainability, and AI integration. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive edge in the market. ## Recent News & Developments In an effort to increase diversity and advance personalized medicine initiatives, the U.S. National Institutes of Health (NIH) extended the All of Us Research Program in June 2025 to include the biospecimens of 500,000 more individuals. In order to strengthen domestic sample integrity and supply, Thermo Fisher Scientific stated in May 2025 that it will invest $2 billion to modernize cold-chain and analytical facilities inside its biobanking division in North America. With £45 million in financing, a partnership led by Genomics England and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) launched Project Genome of Europe in March 2025 with the goal of accelerating pan-EU research collaborations and harmonizing cross-national biobanking standards. In order to strengthen Asia-Pacific research capacity, AIG Hospital in southern India launched its first regional biobank in November 2024 with the goal of collecting and storing over 100,000 tissue and blood samples over the next ten years. Initial results showing effective federated learning deployment across biobanks for multiple sclerosis research were released in October 2024 by the Clinnova effort, a cooperation between France, Germany, Switzerland, and Luxembourg, emphasizing privacy protection and interoperability. The European biobanking network, BBMRI-ERIC, announced in April 2024 that the number of participating institutions had increased by 12%, indicating improved standardization and sample-sharing capabilities. Additionally, around 25% of biobanks in North America explored blockchain initiatives in early 2024 to safeguard data access and sample tracking processes. ## Report Scope | MARKET SIZE 2024 | 75.39(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 78.5(USD Billion) | | MARKET SIZE 2035 | 117.55(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.12% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Thermo Fisher Scientific (US), Qiagen (DE), Illumina (US), Merck KGaA (DE), STEMCELL Technologies (CA), BioLife Sciences (US), Tecan Group (CH), Biosample Solutions (US), ReproCELL (JP) | | Segments Covered | Application, Sample Type, Storage Type, End User | | Key Market Opportunities | Integration of advanced genomic technologies enhances personalized medicine applications in the market. | | Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the biobanking sector. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Biobanking Market as of 2024?** A: The Biobanking Market was valued at 75.39 USD Billion in 2024. **Q: What is the projected market valuation for the Biobanking Market in 2035?** A: The market is projected to reach 117.55 USD Billion by 2035. **Q: What is the expected CAGR for the Biobanking Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Biobanking Market during 2025 - 2035 is 4.12%. **Q: Which application segment is anticipated to have the highest valuation in 2035?** A: The Pharmaceutical Development segment is expected to grow from 30.39 USD Billion to 42.55 USD Billion by 2035. **Q: How does the valuation of the Clinical Trials segment change from 2024 to 2035?** A: The Clinical Trials segment is projected to increase from 20.0 USD Billion to 30.0 USD Billion by 2035. **Q: What are the key sample types in the Biobanking Market and their projected valuations?** A: By 2035, Blood and Tissue samples are expected to reach valuations of 23.0 USD Billion and 30.0 USD Billion, respectively. **Q: Which storage type is projected to dominate the Biobanking Market by 2035?** A: Cryopreservation is anticipated to dominate, with a valuation increase from 30.0 USD Billion to 46.0 USD Billion by 2035. **Q: What is the expected growth in the Biotechnology Companies segment from 2024 to 2035?** A: The Biotechnology Companies segment is projected to grow from 20.0 USD Billion to 30.0 USD Billion by 2035. **Q: Who are the leading players in the Biobanking Market?** A: Key players include Thermo Fisher Scientific, Qiagen, Illumina, and Merck KGaA. **Q: What is the anticipated growth for the RNA sample type by 2035?** A: The RNA sample type is expected to grow from 15.39 USD Billion to 24.55 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/biobanking-market-5967*